Santos M.F., Almorox R.B., Solan L., Lopez O., Gallardo A., Garcia-Avila S., Esquirol A., Ferra C., Martin A., Garcia A., Perez E., Colorado M., Cortes M., Cabrero M., Gayoso J., Yañez L., Pascual M.J., Heras I.D.L., Diez J.L., Caballero M.D., Kwon M., Corral L.L.. CT-275 Incidence and Characteristics of Chronic GVHD in Haploidentical Stem-Cell Transplantation With Post-Transplantation Cyclophosfamide: Experience of the Spanish Group of Hematopoietic Transplantation and Cell Therapy (GETH-TC). Clinical Lymphoma Myeloma & Leukemia. 2022; 22DOI:10.1016/S2152-2650(22)01659-7. PMID:36164212. IF:(Q/D).

Munir T., Moreno C., Owen C., Follows G., Benjamini O., Janssens A., Levin M.-D., Osterborg A., Robak T., Simkovic M., Stevens D., Voloshin S., Vorobyev V., Yagci M., Ysebaert L., Qi Q., Steele A., Schuier N., Baeten K., Caces D.B., Niemann C., Kater A.. CLL-106 First Prospective Data on Minimal Residual Disease Outcomes After Fixed-Duration Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for First-Line Treatment of CLL in Older Adult or Unfit Patients: The GLOW Study. Clinical Lymphoma Myeloma & Leukemia. 2022; 22DOI:10.1016/S2152-2650(22)01322-2. PMID:36163867. IF:(Q/D).

Moreno C., Greil R., Demirkan F., Tedeschi A., Anz B., Larratt L., Simkovic M., Novak J., Strugov V., Gill D., Gribben J.G., Kwei K., Dai S., Hsu E., Dean J.P., Flinn I.W.. First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial. HAEMATOLOGICA. 2022; 107(9)DOI:10.3324/haematol.2021.279012. PMID:35021599. IF:10.100(Q1/2D).

Bazarbachi A., Boumendil A., Finel H., Khvedelidze I., Romejko-Jarosinska J., Tanase A., Akhtar S., Ben Othman T., Ma’koseh M., Afanasyev B., El-Cheikh J., Briones J., Gülbas Z., Hamladji R.-M., Elverdi T., Blaise D., Martínez C., Alma E., Halaburda K., Sousa A.B., Glass B., Robinson S., Montoto S., Sureda A.. Correction: The outcome of patients with Hodgkin lymphoma and early relapse after autologous stem cell transplant has improved in recent years (Leukemia, (2022), 36, 6, (1646-1653), 10.1038/s41375-022-01563-8). LEUKEMIA. 2022; 36(8)DOI:10.1038/s41375-022-01639-5. PMID:35840758. IF:11.400(Q1/1D).

Barr P.M., Owen C., Robak T., Tedeschi A., Bairey O., Burger J.A., Hillmen P., Coutre S.E., Dearden C., Grosicki S., McCarthy H., Li J.-Y., Offner F., Moreno C., Zhou C., Hsu E., Szoke A., Kipps T.J., Ghia P.. Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia. Blood Advances. 2022; 6(11)DOI:10.1182/bloodadvances.2021006434. PMID:35377947. IF:7.500(Q1/2D).

Meijide J.B.. Medicina de precisión en leucemia linfática crónica: Análisis de coste-efectividad de nuevas combinaciones dirigidas. Farmacia Hospitalaria. 2022; 46(3)DOI:10.7399/fh.13280. PMID:36183201. IF:(Q/D).

Gutiérrez-Hernández, MD, Ramil, G, González-Alvarez, N, San-José, P. Reticulocyte Count Interference at the Onset of Acute Myeloid Leukemia. International Journal of Laboratory Hematology. 2025; 47(6)DOI:10.1111/ijlh.14545. PMID:40836604. IF:2.300(Q2/5D).

Torrent, A, Morgades, M, Iacoboni, G, Reguera, JL, Kwon, M, Corral, LL, Hernani, R, Ortiz-Maldonado, V, Sanz, J, Gonzalez, ACC, Guerra, L, Pina, JMS, Mussetti, A, Garcia-Sancho, AM, Bastos-Oreiro, M, Delgado, J, Carpio, C, Sancho, JM, Perez-Martinez, A, Barba, P. Patient selection and treatment outcomes over time in patients with large B-cell lymphoma receiving car T-cell therapy. BONE MARROW TRANSPLANTATION. 2025; 60(12)DOI:10.1038/s41409-025-02722-y. PMID:41028300. IF:5.200(Q1/1D).

Vilaseca, VG, Perez, ES, Fabrego, IE, Peral, IL, Prat, AM. Wolf's isotopic phenomenon in a patient with T-cell lymphoblastic lymphoma. MEDICINA CLINICA. 2025; 165(5)DOI:10.1016/j.medcli.2025.107073. PMID:40543401. IF:2.100(Q2/3D).

Fasanella, MG, Mozos, A, Briones, J, Nomdedeu, JF, Novelli, S. Evaluation of Clinical Outcomes and Treatment Complications in Hairy Cell Leukemia: A Single-Center Retrospective Analysis. Cancer Reports. 2025; 8(10)DOI:10.1002/cnr2.70356. PMID:41031578. IF:(Q/D).

Tolosa-Ridao, C, González, MB, Gómez, MA, Fox, L, Artigas, MDP, Santamaria, A, González, MDQ, Salinas, AS, Camacho, JMS, Alvaro, VI, Abdallahi-Lefdil, Z, Navascues, JC, Pardo, L, Fernández-Luis, S, Suárez, LPV, Villar, S, Beorlegui-Murillo, P, Esquirol, A, García, II, Ribes-Amorós, J, Lavilla, E, Lopez-Marín, J, Basalobre, P, Filaferro, S, Cedillo, A, Bento, L, Sureda, A, Salas, MQ. Frailty dynamics and their impact on QoL in patients undergoing autologous HCT for multiple myeloma: Results from a multicentre GETH-TC study. BRITISH JOURNAL OF HAEMATOLOGY. 2025; 207(4)DOI:10.1111/bjh.70068. PMID:40796522. IF:3.800(Q1/3D).

Osuna-Gómez, R, López-Pardo, J, Mulet, M, Nomdedéu, J, Cantó, E, Ortin, R, Cayuela, AS, Ortiz, MA, Guinart-Cuadra, A, Vidal, S. Non-Competitive Binding of Isatuximab and Daratumumab to CD38: Implications for Targeted Therapy in Multiple Myeloma. Pharmaceutics. 2025; 17(10)DOI:10.3390/pharmaceutics17101278. PMID:41155915. IF:5.500(Q1/1D).

Torrent-Rodríguez, A, Cascos, E, Garcés, VN, Pérez-López, E, Baile-González, M, Rodríguez, CM, Cascón, MJP, Luque, M, Esquirol, A, Calvo, CM, Peña-Muñoz, F, Fernando, IH, Ormtegi, IO, Marín, AJS, Fernández-Luis, S, Domínguez-García, JJ, Fernández, SV, Lorenzo, JLL, Girón, MFD, Pinedo, LG, García-Maño, L, González-Rodriguez, AP, Torrado, T, Filaferro, S, Basalobre, P, Ortí, G, Rovira, M, Chacón, MJ, Salas, MQ. Safety of Post-Transplant Cyclophosphamide-Based Prophylaxis in AML Patients with Pre-Existing Cardiac Morbidity Undergoing Allogeneic Hematopoietic Cell Transplantation. Cancers. 2025; 17(19)DOI:10.3390/cancers17193128. PMID:41097656. IF:4.400(Q2/3D).

Lewis, JFM, Daver, NG, Robinson, NJ, Pandya, BJ, Pierre-Louis, B, Monir, S, Sierra, J. Prevalence of Fms-Like Tyrosine Kinase 3 (FLT3) Mutations in Patients With Acute Myeloid Leukaemia: A Systematic Literature Review and Meta-Analysis. Cancer Medicine. 2025; 14(18)DOI:10.1002/cam4.71205. PMID:40981231. IF:3.100(Q2/5D).

Perruccio, K, Ward, KN, Tridello, G, Knelange, N, Zeiser, R, Franke, GN, Sirvent, A, Einsele, H, Vicent, MG, Navarro, JMF, Contentin, N, Collin, M, Martino, R, Gambella, M, Sengeloev, H, Passweg, J, Snowden, J, Nagler, A, Kulagin, A, Gabriel, M, Kröger, N, Cascon, MJP, Yeshurun, M, Güngör, T, Robin, C, Clark, A, Duarte, ML, Amor, AA, Itala-Remes, M, Mikulska, M, Styczynski, J, de la Camara, R, Ljungman, P, Averbuch, D, Cesaro, S. Clinical characteristic and outcome of HHV-6 encephalitis after allogeneic hematopoietic cell transplantation: A study of Infectious Disease Working Party of EBMT. BONE MARROW TRANSPLANTATION. 2025; 60(9)DOI:10.1038/s41409-025-02638-7. PMID:40461849. IF:5.200(Q1/1D).

Fernandez, RA, Arroyo, A, Cedena, MT, Rosiñol, L, De la Rubia, J, Miqueleiz, S, González-Calle, V, de Arriba, F, Casado-Montero, F, Hernandez, MT, Mas, M, Fernandez-Abellan, P, Rodriguez-Otero, P, Calle, C, Abella, E, Ribas, P, Alegre, A, Bergua, JM, Ocio, E, De la Cruz, J, Mateos, MV, San-Miguel, J, Bladé, J, Lahuerta, JJ, Martinez-Lopez, J. Characteristics of Long-Term Survivors in Multiple Myeloma: Exploring Factors for Cure After Extended Follow-Up. Clinical Lymphoma Myeloma & Leukemia. 2025; 25DOI:. PMID:. IF:2.700(Q2/4D).

Giménez, E, Cadenas, IG, Piñana, JL, Albert, E, Vázquez, L, Avendaño, A, Cabrero, M, Esquirol, A, Martino, R, López-Jiménez, J, Cuesta, MA, Humala, K, Villar, S, Rovira, M, Heras, I, Zudaire, T, Arroyo, I, Zabalza, A, Aguado, B, Solano, C, Navarro, D. Cytomegalovirus DNA Doubling Time for Early Identification of Clinically Significant Infection Episodes in Allogeneic Hematopoietic Stem Cell Transplant Recipients Undergoing Primary Letermovir Prophylaxis: A Multicenter Study. Transplant Infectious Disease. 2025; 27(5)DOI:10.1111/tid.70080. PMID:40674366. IF:2.600(Q1/1D).

Pinana, JL, Martino, R, Cesaro, S, Averbuch, D, Lujgman, P. To proceed or delay? The dilemma of community-acquired respiratory viruses in adults and pediatrics before allogeneic stem cell transplantation and chimeric-antigen-receptor T-cell therapy. CURRENT OPINION IN INFECTIOUS DISEASES. 2025; 38(4)DOI:10.1097/QCO.0000000000001120. PMID:40471062. IF:4.000(Q1/2D).

Chorao, P, Avendano, A, Heras, I, Aiello, F, Micó-Cerdá, M, Bel, AA, Garcia-Gutierrez, V, Olave, MT, Gómez, MA, Espigado, I, Cuesta-Casas, MA, González-Santillana, C, Hernández-Rivas, JA, Roldán-Pérez, A, Labrador, J, Villalba, M, Vázquez, L, Vidal, CG, Martino, R, López-Jiménez, J, Cedillo, A, Solano, C, García-Cadenas, I, Piñana, JL. Co-infections during SARS-CoV-2 infection in hematologic patients and cell therapy recipients in the omicron era: a Spanish hematopoietic stem cell transplantation and cell therapy group study. BMC INFECTIOUS DISEASES. 2025; 25(1)DOI:10.1186/s12879-025-11302-w. PMID:40713537. IF:3.000(Q2/4D).

Nath, K, Zhang, MJ, Bye, M, Abid, MB, Benjamin, C, Betts, B, Bhatt, NS, Bolanos, EA, Bolon, YT, Gadalla, SM, Grunwald, MR, Krem, MM, Lee, SJ, Marsh, SGE, Martino, R, Mehta, PA, Milano, F, Prestidge, T, Saultz, JN, Shaw, BE, Spellman, SR, Choe, H, Shaffer, BC. Transplant outcomes using older matched sibling donors compared with young alternative donors: a CIBMTR analysis. Blood Advances. 2025; 9(14)DOI:10.1182/bloodadvances.2024014858. PMID:40048743. IF:7.100(Q1/2D).